For example, on August 16, 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law, which among other things, (i) extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025, (ii) authorizes HHS to negotiate the price of certain high-expenditure, single-source drugs covered under Medicare that have been on the market for at least 7 years, and (iii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation.
All entries for: Hematology
March 9, 2026
Editas Medicine
Neutral Outlook
Cambridge, MA
201-500 employees
On August 16, 2022, the Inflation Reduction Act of 2022 (“IRA”) was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years
Disease Area: Cardiology, Hematology, Immune Diseases, Metabolic Diseases, Oncology, Rare Diseases
Drug Type: Biologic
March 9, 2026
ALX Oncology Holdings Inc
Negative Outlook
South San Francisco, CA
51-200 employees
In August 2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes….The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.
Disease Area: Hematology, Oncology
Drug Type: Biologic
March 5, 2026
GSK plc
Negative Outlook
London, England
10,000+ employees
In ovarian cancer, Zejula saw a decrease in sales, driven by ongoing volume reductions, including impacts of an FDA labelling update restricting use to certain patient populations, and the impacts of IRA Medicare Part D redesign in the US
Disease Area: Antiviral, Chronic Disease, Gastrointestinal, Hematology, Immune Diseases, Infectious Diseases, Metabolic Diseases, Oncology, Respiratory Diseases
Drug Type: Biologic, Small Molecule
March 5, 2026
CorMedix Inc
Negative Outlook
Parsippany, NJ
1-50 employees
“In particular, there have been several recent U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as executive orders and sub-regulatory guidance that may impact pricing for pharmaceutical products. These initiatives include, among others… implementation of the inflation Reduction Act of 2022 (Inflation Reduction Act), including provisions that generally require manufacturers of Medicare Part B and Part D drugs to pay inflation rebates to the Medicare program if pricing metrics associated with their products increase faster than the rate of inflation;”
Disease Area: Cardiology, Hematology, Infectious Diseases
Drug Type: Biologic, Small Molecule
March 5, 2026
Caribou Biosciences
Neutral Outlook
Berkeley, CA
51-200 employees
Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry and the pricing of products.
Disease Area: Hematology, Oncology
Drug Type: Biologic
March 5, 2026
HUTCHMED (China) Ltd
Negative Outlook
Hong Kong
1,001-5,000 employees
The IRA, or other federal or state laws, could affect the market conditions for, or pricing or reimbursement of, our products. There is no assurance that federal or state health care reform will not adversely affect our future business and financial results.
Disease Area: Dermatology, Hematology, Immune Diseases, Oncology
Drug Type: Biologic, Small Molecule
March 4, 2026
Cellectar Biosciences
Neutral Outlook
Florham Park, NJ
1-50 employees
Additionally, in August 2022, President Biden signed into law the Inflation Reduction Act of 2022, which implements substantial changes to the Medicare program, including drug pricing reforms and creation of new Medicare inflation rebates
Disease Area: Hematology, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
March 4, 2026
TScan Therapeutics
Neutral Outlook
Waltham, MA
51-200 employees
The outcome of these challenges on the IRA, and the effects of the IRA on our business and the healthcare industry in general are not yet known.
Disease Area: Hematology, Immune Diseases, Oncology
Drug Type: Biologic